5 year cohort study showed that obese T2D (diabetes) pts, semaglutide significantly lowered risk of osteoporosis (HR 0. 61), & gout (HR 0. 63) vs sitagliptin. Semaglutided did not lower the risk of Knee (HR 1. 05) or hip osteoarthritis (HR 0. 88). https://t.co/MqMBKdsXlu https://t.co/VWIGIDhPMO
Links:
Comparative analysis of GLP-1 receptor agonists, traditional glucose-lowering m…
https://buff.ly/QVSa1Cb
May-31-2025
